Grifols ever-evolving portfolio is focused on innovation in new products and therapies, continued improvement across all areas and new advances in industrial manufacturing systems and processes.
This table provides an overview of projects of Bioscience division in development:
- All projects
- Advanced therapies
- Intensive care
Research / Pre-Clinical
Potential new indication for this factor VIII clotting concentrate
New therapeutic indication with intravenous immunoglobin
New product to treat deficiencies
New indication for this antithrombin product
Brief description: New indication for this fibrin sealant
Registration / Post-Launch
Brief description: New presentation for increased user convenience
A new product to subcutaneously treat primary immunodeficiency to offers greater convenience to patients
Products and services
How can we help you?
Grifols R&D+i projects focus on broadening the therapeutic potential of plasma proteins, enhancing the safety of blood transfusions, creating new solutions for hospital pharmacies and advancing intravenous therapies.
Financial and regulatory information for investors and shareholders.
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?